Retinal Pigment Epithelium Safety Study For Patients In B4711001

General Information

Summary This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
Clinical trials phase Long term follow up
Start date (estimated) 2016-09-21
End date (estimated) 2020-10-04
Clinical feature
Label wet macular degeneration
Link http://www.ebi.ac.uk/efo/EFO_0004683
Description A form of RETINAL degeneration in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.; A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.

Administrative Information

NCT Number NCT03102138
EudraCT Number 2015-002267-42
Other study identifiers
Name B4711005
Regulatory body approval
Country
Public contact
Country
Sponsors Pfizer

Cell Line

Stem cell lines obtained from

Recruitment

Recruitment Status Active, not recruiting
Estimated number of participants 10